EB-002

Last updated

EB-002
Clinical data
Other namesEB002; EB-373; EB373; Synthetic psilocin prodrug
Routes of
administration 		Oral [1]
Drug class Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. [1] [2] [3] [4] It is taken by mouth. [1] The drug is under development by Enveric Biosciences. [1] [2] [3] As of November 2024, it is in the preclinical research stage of development. [1] [2] In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million. [3] Its exact chemical structure does not yet appear to have been disclosed. [1]

Contents

See also

References

  1. 1 2 3 4 5 6 "Enveric Biosciences". AdisInsight. 22 November 2024. Retrieved 16 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on EB-373 with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. 1 2 3 Jackson A (12 November 2024). "Enveric inks $62M licensing deal for psilocin prodrug". Green Market Report. Retrieved 16 February 2025.
  4. ↑ "Investigational Psilocin Prodrug Gains Patent Protection for Sleep Disorder Applications". Sleep Review. 18 July 2024. Retrieved 16 February 2025.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.